FFN
ZVRA icon

Focus Financial Network’s Zevra Therapeutics ZVRA Stock Holding History

Focus Financial Network’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,500
Closed -$141K – 772
2023
Q4 		$141K Buy
+21,500
New +$101K 0.01% 696

Other funds holding ZVRA

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Focus Financial Network's ZVRA Position: Q1 2024 in Review

Focus Financial Network sold out of Zevra Therapeutics (ZVRA) in Q1 2024, closing a stake of 21,500 shares — an estimated $141K sold.

Focus Financial Network first reported a position in ZVRA in Q4 2023 and held it in 1 quarter. The position peaked at $141K in Q4 2023. 89 funds tracked by Wall St. Rank hold ZVRA as of Q1 2024.

  • Focus Financial Network reported no remaining Zevra Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Focus Financial Network sold 21,500 Zevra Therapeutics shares in Q1 2024, an estimated $141K.
  • Focus Financial Network first reported a position in Zevra Therapeutics in Q4 2023 and held it in 1 quarter.
  • Focus Financial Network's Zevra Therapeutics position peaked at $141K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2024.

Based on Focus Financial Network's 13F filing for Q1 2024, filed 24 Apr 2024.